SAN
DIEGO, July 6, 2023 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused
on developing products to treat cancer and life threatening
infectious diseases, today announced the appointment of
Nicolas Gikakis to its Board of
Directors (Board), effective July 3,
2023. Mr. Gikakis will also serve as a member of the
Nominating and Corporate Governance Committee of the Board. In
connection with the appointment of Mr. Gikakis as a director, the
authorized size of Aethlon Medical's Board was increased to six
members.
"Nick is a seasoned, global medical device and biomedical
industry executive with over 20 years' experience including
high-profile positions," stated Charles J.
Fisher, Jr. M.D., Chief Executive Officer of Aethlon
Medical. "I am pleased to welcome Nick to our Board of Directors
and look forward to leveraging his extensive experience and
relationships as we continue to pursue the research and clinical
development of the Hemopurifier®, a therapeutic blood filtration
system that can bind and remove harmful exosomes and
life-threatening viruses from blood and our investigation of its
utility in the organ transplant market."
"The potential of the Hemopurifier within oncology and as a
potential treatment for life-threatening diseases, as well as the
organ transplant market is vast and I am excited to join the Board
at such an important stage for the company," stated Mr. Gikakis. "I
look forward to working with my fellow directors and the entire
Aethlon leadership team as we strive to position the company for
long-term growth and value creation."
From 2021 to May 2023, Mr. Gikakis
served as the Head of Commercial for WearOptimo Pty Ltd, a private
Australian medical device and digital health company. Previously,
from 2017 to 2019, Mr. Gikakis was Vice President of Strategy and
Corporate Development at Oventus Medical Limited, a private medical
device company, during which time he assisted with the commercial
expansion of its sleep apnea device. From 2012 to 2021, Mr. Gikakis
held various leadership and independent strategic advisor positions
in the healthcare industry in sales, marketing, product
development, and corporate development and transactions, including
for companies working with blood filtration and purification.
Mr. Gikakis earned a BS in bioengineering from the University of Pennsylvania and holds an MBA from
George Mason University, with earlier
work in bench and clinical research, and clinical experience at the
University of Pennsylvania.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening
viral infections. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and harmful
exosomes from blood utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where
exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. The Hemopurifier also
holds an FDA Breakthrough Device designation and an open
Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that involve risks and uncertainties. Statements
containing words such as "may," "believe," "anticipate," "expect,"
"intend," "plan," "project," "will," "projections," "estimate,"
"potentially" or similar expressions constitute forward-looking
statements. Such forward-looking statements are subject to
significant risks and uncertainties and actual results may differ
materially from the results anticipated in the forward-looking
statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Factors that may
contribute to such differences include, without limitation, the
Company's ability to successfully complete development of the
Hemopurifier and to successfully demonstrate the utility of the
Hemopurifier combatting cancer and life-threatening viruses and in
the organ transplant field, the Company's ability to manage its
clinical trials, the Company's ability to raise additional funds,
and other potential risks. The foregoing list of risks and
uncertainties is illustrative, but is not exhaustive. Additional
factors that could cause results to differ materially from those
anticipated in forward-looking statements can be found under the
caption "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended March 31, 2023,
and in the Company's other filings with the Securities and Exchange
Commission, including its Quarterly Reports on Form 10-Q. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except as may be
required by law, the Company does not intend, nor does it undertake
any duty, to update this information to reflect future events or
circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-appoints-medical-device-and-biomedical-executive-nicolas-gikakis-to-its-board-of-directors-301871469.html
SOURCE Aethlon Medical, Inc.